NCT05506969View on ClinicalTrials.gov

Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

October 3, 2023

Study Completion Date

April 26, 2024

Conditions
Plague, PneumonicPlagueVaccine-Preventable Diseases
Interventions
BIOLOGICAL

rF1V-1018

rF1V vaccine and CpG 1018® adjuvant

BIOLOGICAL

rF1V vaccine

rF1V vaccine

Trial Locations (6)

20850

Optimal Research Maryland, Rockville

92108

Optimal Research California, San Diego

35802-2569

Optimal Research Alabama, Huntsville

32934-8172

Optimal Research Florida, Melbourne

61614-4885

Optimal Research Illinois, Peoria

78705-2655

Optimal Research Texas, Austin

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Dynavax Technologies Corporation

INDUSTRY